Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma-Reference-Cited by-同舟云学术

Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma

Published:2021-04-12 Issue:6 Volume:73 Page:e1372-e1375
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Lee Soon Kyu¹²,Sung Pil Soo¹²^ORCID,Park Sung-Soo³^ORCID,Min Chang-Ki³,Nam Heechul¹²,Jang Jeong Won¹²,Choi Jong Young¹²,Yoon Seung Kew¹²

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

2. The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

3. Division of Hematology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Abstract

Abstract The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.

Funder

Catholic University of Korea

Korean Association for the Study of the Liver

Korean Liver Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab302/39615752/ciab302.pdf

Reference13 articles.

1. Daratumumab in multiple myeloma;Nooka;Cancer,2019